<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02499198</url>
  </required_header>
  <id_info>
    <org_study_id>1502M63481</org_study_id>
    <secondary_id>R01CA180880</secondary_id>
    <nct_id>NCT02499198</nct_id>
  </id_info>
  <brief_title>Labeled Nornicotine in Smokeless Tobacco</brief_title>
  <official_title>Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Smokeless tobacco users who are unable or unwilling to quit tobacco use may be exposed to the
      potent oral and esophageal carcinogen NNN not only from tobacco itself, but also via its
      endogenous synthesis from nornicotine. The proposed study will lead to an understanding of
      the endogenous formation of NNN from nornicotine in humans, and will also investigate the
      effect of the reduction of nornicotine content in smokeless tobacco on the extent of
      endogenous NNN formation. The knowledge gained in this study will lead to the development of
      recommendations for the regulation, or potentially elimination, of nornicotine in smokeless
      tobacco products in order to minimize exposure to NNN in the users of these products.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The tobacco alkaloid nornicotine is a precursor to N'-nitrosonornicotine (NNN), a potent
      tobacco-specific carcinogen. NNN is believed to play an important role in the induction of
      esophageal and oral cavity cancers in tobacco users. Nornicotine contributes to NNN exposure
      in tobacco users in two ways. In addition to being a precursor to NNN formation in tobacco,
      it may also be nitrosated endogenously. Endogenous nitrosation of nornicotine that is present
      in tobacco products can occur in the oral cavity, in the stomach, or elsewhere in the body of
      tobacco users. This is particularly relevant to the use smokeless tobacco products - a form
      of tobacco that is kept in the oral cavity for prolonged periods of time, creating favorable
      conditions for nornicotine nitrosation. Given the high carcinogenic potency of NNN and the
      association of smokeless tobacco use with oral and esophageal cancers, regulation of
      nornicotine content in smokeless tobacco products is urgently needed. The Food and Drug
      Administration (FDA) has authority to regulate harmful and potentially harmful tobacco
      constituents under the Family Smoking Prevention and Tobacco Control Act. The information on
      the extent of endogenous nitrosation of nornicotine as a function of its content in smokeless
      products is crucial for the adequate regulation of this tobacco constituent by the FDA. Aims
      of this proposal are: (1) To determine the variation of nornicotine content in smokeless
      products currently marketed in the U.S. There is no information on nornicotine content in
      individual smokeless brands, and the extent of variation among the currently marketed U.S.
      products is unknown. Aim 1 will address this important gap and will also provide critical
      information for Aim 2 of this proposal. (2) To investigate the endogenous formation of NNN in
      smokeless tobacco users. Smokeless tobacco users will be randomized to a tobacco-free herbal
      snuff containing various amounts of stable isotope-labeled nornicotine added to it.
      Isotope-labeled urinary total NNN - a biomarker of exposure to NNN - will be measured in
      these subjects by using liquid chromatography-tandem mass-spectrometry. This methodology will
      allow for specific identification of urinary total NNN from endogenous nitrosation of
      nornicotine, versus that resulting from exposure to NNN in tobacco products. The effect of
      nornicotine reduction on the extent of endogenous NNN formation will be studied by gradually
      decreasing the amount of isotope-labeled nornicotine added to study snuff. The results of
      this study will provide extremely important new information on the endogenous formation of
      the carcinogenic nitrosamine NNN upon exposure to nornicotine from tobacco use. An
      understanding of this process is absolutely necessary for the adequate regulation of
      nornicotine in tobacco products with the purpose of minimizing public harm.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endogenous formation of NNN in smokeless tobacco users after exposed to known amount of nornicotine using urine analysis</measure>
    <time_frame>baseline, 3 days, up to 20 days</time_frame>
    <description>Urinary excretion daily for 1 day prior and 3 days after 30 minutes exposure, on 3 separate occasions, 20 days apart</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Tobacco Toxicity</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nornicotine level equal to highest commercial smokeless tobacco tested</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nornicotine level equal to mean of commercial smokeless tobaccos</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nornicotine level equal to lowest commercial smokeless tobacco tested</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nornicotine level equal to 50% of commercial smokeless tobaccos</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nornicotine level equal to 10% of commercial smokeless tobaccos</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nornicotine level equal to 5% of commercial smokeless tobaccos</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group - Herbal snuff only, no Nornicotine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[D4]Nornicotine - Highest</intervention_name>
    <description>Level equal to highest level of [D4]Nornicotine found in commercial tobacco based snuff</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>[pyridine-D4]nornicotine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[D4]Nornicotine - Mean</intervention_name>
    <description>Level equal to mean level of [D4]Nornicotine found in commercial tobacco based snuff</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>[pyridine-D4]nornicotine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[D4]Nornicotine - Lowest</intervention_name>
    <description>Level equal to lowest level of [D4]Nornicotine found in commercial tobacco based snuff</description>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>[pyridine-D4]nornicotine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[D4]Nornicotine - 50% Lowest</intervention_name>
    <description>Level equal to 50% of the lowest level of [D4]Nornicotine found in commercial tobacco based snuff</description>
    <arm_group_label>Arm 4</arm_group_label>
    <other_name>[pyridine-D4]nornicotine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[D4]Nornicotine - 10% Lowest</intervention_name>
    <description>Level equal to 10% of the lowest level of [D4]Nornicotine found in commercial tobacco based snuff</description>
    <arm_group_label>Arm 5</arm_group_label>
    <other_name>[pyridine-D4]nornicotine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[D4]Nornicotine - 5% Lowest</intervention_name>
    <description>Level equal to 5% of the lowest level of [D4]Nornicotine found in commercial tobacco based snuff</description>
    <arm_group_label>Arm 6</arm_group_label>
    <other_name>[pyridine-D4]nornicotine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>13C6-NNN</intervention_name>
    <description>0.5Âµg/g - below traditional levels found in moist snuff</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>13C6-N'-nitrosonornicotine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Herbal Snuff</intervention_name>
    <description>A tobacco-free herbal snuff, such as Smokey Mountain or similar</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Adults who are regular smokeless tobacco users

          2. Subjects are in good physical health and good general oral health;

          3. Subjects are in stable, good mental health
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irina Stepanov, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanna Vanderloo, MSN</last_name>
    <phone>612-624-4983</phone>
    <email>hannav@umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joni Jensen, MPH</last_name>
    <phone>612-624-5178</phone>
    <email>jense010@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nornicotine</keyword>
  <keyword>Tobacco</keyword>
  <keyword>N'-nitrosonornicotine</keyword>
  <keyword>NNN</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lobeline</mesh_term>
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

